← Eichor
Study identifier: NCT06772142 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Early Feasibility of the Nervonik Peripheral Nerve Stimulation Device

Condition: Peripheral Nerve Disorder  ·  Sponsor: Nervonik

PhaseEARLY_Phase 1
Planned participants30
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

A multicenter, 30 patient prospective single arm evaluation of the Nervonik system in symptomatic patients with chronic severe knee, elbow or shoulder pain. COHORT 1: The initial cohort of patients will receive the Nervonik neurostimulator for up to 8 hours. The patient will remain local to the care facility for implant stimulator program changes until the patient is satisfied with the degree of pain relief. The implant will be removed from the patient at the end of the evaluation. COHORT 2: The second cohort of patients will include those patients from cohort 1 who have determined the Nervonik implant provides suitable pain relief and agree to have a permanent implant placed. In addition, the second cohort includes non-cohort one patients meeting the trial requirements and agreeing to participate in the trial.

This description comes directly from the study's public registry record.

Talk to the study team

Depatment Chairman, Neurology  ·  5072048000  ·  dr.ricardo.bermudez@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Punta PacificaPanama City, Provincia de Panamá, PanamaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06772142